Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Selvita has entered into an agreement with Germany-based Evestra to deliver a range of drug metabolism, pharmacokinetic (DMPK) and physicochemical studies.
Subscribe to our email newsletter
Under the contract, the companies will work on drug metabolism and pharmacokinetics studies, including CYP inhibition, metabolic identification and stability.
It will also include metabolic identification and stability, as well as oral bioavailability and pharmacokinetics assays, both in-vitro and in-vivo, accompanied by gentotoxicity testing.
Selvita Biology Department head Milosz Gruca said Evestra’s choice to entrust Selvita with their project is not only a nobilitation for them, but also gives their research team a chance to show their potential and capabilities to run complex projects in yet another field of preclinical research.